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Mutations in the HFE Gene and Cardiovascular
Disease Risk
An Individual Patient Data Meta-Analysis of 53 880 Subjects
Daphne L. van der A, PhD; Maroeska M. Rovers, PhD; Diederick E. Grobbee, MD, PhD;
Joannes J.M. Marx, MD, PhD; Jill Waalen, MD, MPh; Christina Ellervik, MD, PhD;
Børge G. Nordestgaard, MD, DMSc; John K. Olynyk, MD; Peter R. Mills, MD;
James Shepherd, FRCP; Bernard Grandchamp, MD, PhD; Jolanda M.A. Boer, PhD;
Calogero Caruso, MD; Marcello Arca, MD; Beat J. Meyer, MD; Yvonne T. van der Schouw, PhD
Background—Whether mutations in the hemochromatosis (HFE) gene increase cardiovascular disease risk is still
undetermined. The main reason is the low frequency of the mutations, in particular of the compound C282Y/H63D
genotype. We combined the data of 11 observational studies for an individual patient data meta-analysis.
Methods and Results—Individual patient data were obtained from published as well as unpublished studies that had
information available on the C282Y mutation as well as the H63D mutation in relation to coronary heart disease risk.
Individual records were provided on each of the 53 880 participants in 11 studies. In total, 10 541 patients with coronary
events were documented, of whom 5724 had an acute myocardial infarction. The crude and adjusted association between
HFE genotypes and coronary events was examined by logistic regression analysis. We explored potential effect
modification of the association between traditional cardiovascular risk factors and coronary events by HFE genotypes.
After full adjustment, the odds ratio for coronary heart disease was 1.12 (95% CI, 0.92 to 1.37) for subjects with the
compound heterozygous (C282Y/H63D) genotype relative to those with the wild-type/wild-type genotype. The odds
ratios for C282Y/C282Y, C282Y/wild-type, H63D/H63D, and H63D/wild-type were 0.78 (95% CI, 0.49 to 1.26), 0.98
(95% CI, 0.90 to 1.07), 1.16 (95% CI, 0.97 to 1.38), and 1.07 (95% CI, 1.00 to 1.14), respectively. There was no
evidence for effect modification.
Conclusions—The results of this large individual patient data meta-analysis do not support the view that HFE gene
mutations are associated with an increased risk of coronary heart disease or acute myocardial infarction. (Circ
Cardiovasc Genet. 2008;1:43-50.)
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In the early 1980s, Sullivan1 proposed that an increase in bodyiron levels and subsequent oxidative stress may play a role in
the occurrence of cardiovascular disease. A first report in 1992
that serum ferritin concentrations 200 g/L were associated
with a 2-fold increased risk of acute myocardial infarction
(AMI) in men2 fueled much new research from both experimen-
tal and epidemiological studies.3
Clinical Perspective see p 50
Up until 1996, blood markers of iron status and dietary iron
intake were mostly studied as indicators of iron exposure, but
from that year on new opportunities for research were opened
because of the discovery of the hemochromatosis-related
gene (HFE).4 The 2 most important mutations in the HFE
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gene, 282C3Y and 63H3D, have both been associated with
varying degrees of iron overload5 and could be viewed as a
marker of lifelong exposure to increased iron levels.
Despite extensive research, the exact mechanism of the
HFE protein in iron metabolism is still elusive. There is
evidence that HFE competes with transferrin for binding to
the transferrin receptor, thereby lowering its affinity for
iron-containing transferrin and downregulating the uptake of
iron in the cells.6,7 The 2 mutations C282Y and H63D appear
to be in complete linkage disequilibrium. Whereas the C282Y
mutation disrupts the formation of the disulfide bridge nec-
essary for a proper cell-surface expression of the HFE
protein, the functionality of H63D is less well established.
Last year, we reported the results of a conventional
meta-analysis of HFE genotypes and cardiovascular disease
risk using aggregated data, indicating no increased risk.8
However, definitive conclusions could not be drawn because
we could not study the effect of the joint HFE mutations and
make a clear distinction between single heterozygous and
compound heterozygous subjects. The latter group expresses
higher biochemical iron indices than single heterozygotes.9
Most publications to date, including our own, lack the
statistical power for such a comparison and have therefore not
presented data for combined genotypes.
To be able to study the effect of the combined C282Y and
H63D mutations on the risk of cardiovascular disease, we
conducted an individual patient data (IPD) meta-analysis for
which we collected all published and (known) unpublished
individual data on the association between HFE mutations
and coronary heart disease (CHD). In addition, we investi-
gated the possibility of interaction between the HFE gene and
classic risk factors for cardiovascular disease.
Methods
Study Selection, Data Collection, and End Points
Studies were identified by searching PubMed from 1996 until
August 2007 with the use of the strategy ([“Hemochromatosis”
{MeSH}] OR “Hemochromatosis” OR “HFE”] AND [“Myocardial
infarction” {MeSH} OR “Coronary” OR “Heart disease”]) and
hand-searching the reference lists for additional articles. Our search
was limited to the English language. From our global search, studies
were identified that fulfilled the following criteria: (1) association
study in human subjects; (2) genotype data available on both the
HFE 282C3Y and 63H3D mutations; and (3) “hard” end points of
CHD. Studies on intermediate phenotypes such as intima-media
thickness were excluded. We did not limit the search to studies of 1
specific study design but included case-control as well as prospective
and cross-sectional studies.
The principal investigators of all eligible studies were asked for
the raw data of their studies. The obtained data were thoroughly
checked for consistency, plausibility, and integrity of follow-up. Any
queries were resolved by the responsible investigator or statistician.
Cardiovascular end points were coded by the investigators accord-
ing to the International Classification of Diseases (ICD) version 9 or
10, and if no ICD code was available, we asked for a description of
the end point as detailed as possible. End points were classified as
CHD ([unstable] angina, AMI, acute and chronic ischemia; or ICD-9
codes 410 to 414, 427.5; 798.1, 798.2, 798.9; or ICD-10 codes I10 to
I25) and AMI (AMI or ICD-9 code 410 or ICD-10 codes I21 and
I22). Current smoking status was categorized into yes/no. Hyperten-
sion was defined as a measured systolic blood pressure
160 mm Hg and/or diastolic blood pressure 95 mm Hg and/or
treatment for hypertension. Hypercholesterolemia was defined as
fasting total cholesterol 5.0 mmol/L or nonfasting total cholesterol
8.0 mmol/L. Diabetes was defined as fasting glucose 7.0 mmol/L
or nonfasting glucose 11.1 mmol/L and/or treatment for diabetes.
For the exploration of interaction, age was divided into 2 groups
based on the median value in the data set.
Before analysis, data were checked and coded in a standard
fashion and entered into a common database. All data sets were
analyzed as case-control comparisons, including the studies that
were by origin prospective or cross-sectional in design. The articles
by Hetet et al10 and Candore et al11 included 2 different studies, and
they were treated as such in our analyses. The article by Ellervik
et al12 was based on a case-control and a prospective study, using
1 and the same control group. We therefore combined the data and
analyzed the cases from the case-control study and the cases from
the prospective study as 1 group and compared them with the
controls.
Table 1. Characteristics of the Participating Study Populations
Authors Country Design CHD Cases/Controls, n AMI Cases, n Frequency 282Y Allele† Frequency 63D Allele†
Battiloro et al15 Italy Case-control 171/187 171 0.8 (0–1.9) 16.3 (12.8–20.1)
Hetet et al10 United Kingdom Case-control 564/570 564 10.2 (8.5–11.9) 14.8 (12.7–16.9)
France Case-control 152/117 152 6.4 (3.4–9.4) 17.5 (13.3–22.2)
Claeys et al20 Switzerland Case-control 177/89 177 5.1 (2.3–8.4) 17.4 (12.4–23.6)
Fox et al19 Australia Cross-sectional 273/2053 173 8.0 (7.2–8.8) 15.1 (14.0–16.2)
Waalen et al18 United States Cross-sectional 3286/27 763 1121 6.3 (6.1–6.5) 14.8 (14.5–15.1)
Candore et al11 Italy (north) Case-control 172/207 172 1.7 (0.7–2.9) 15.7 (12.6–19.1)
Italy (south) Case-control 77/172 77 0 12.5 (9.3–15.7)
Campbell et al21 United Kingdom Case-control 1255/493 828 10.7 (8.8–12.6) 15.2 (13.0–17.4)
Gunn et al22 United Kingdom Nested case-control 482/1104 411 8.4 (7.2–9.5) 14.2 (12.7–15.5)
Ellervik et al12 Denmark Prospective Case-control 3539/8080 1682 5.5 (5.2–5.9) 12.5 (12.0–13.0)
Van der A et al8 Netherlands Prospective 207/1465 69 5.4 (4.5–6.2) 14.0 (12.8–15.3)
Cobbaert et al23* Netherlands Prospective 159/1066 127 6.6 (5.5–7.6) 14.1 (12.7–15.7)
*The unpublished study by Cobbaert et al23 was undertaken within the Monitoring Project on Disease Risk Factors, a large survey of cardiovascular risk factors
in the Netherlands.39
†Percentages and 95% CIs in control subjects.
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Data Analysis
The PROC ALLELE procedure in the SAS/Genetics package was
used to compute allele frequencies for each study and to test
genotype frequencies for deviation from Hardy-Weinberg equilib-
rium with a 2 goodness-of-fit test.
To decide whether pooling was justified, heterogeneity between
studies was assessed for carriers of the 282Y and 63D allele
separately, with the use of the I-square.13 Because the I-square for
both the 282Y allele and 63D allele was lower than 25% (ie, 8.5%
and 0%, respectively), pooling was indeed justified and performed.
Combined HFE genotypes were attributed to each individual. Our
primary hypothesis was to study the effect of HFE genotypes on
CHD risk by case-control comparisons using unmatched logistic
regression analysis. The minimum detectable odds ratio (OR) was
calculated with the use of the statistical program POWER (version
1.30; Epicenter software) by assuming a  of 0.20 (power of 80%)
and an  of 0.05 (2-sided). For example, for compound heterozy-
gotes, our sample size would be able to detect a true OR of 1.23 for
CHD and 1.30 for AMI. The analyses performed were based on a
complete-case analysis including only those subjects for which
information was available on all covariates in the model. This
yielded some problems when we adjusted our models for classic
cardiovascular risk factors such as smoking, diabetes, hypercholes-
terolemia, and hypertension. The study by Candore et al11 contained
control sets for which information on these risk factors was unavail-
able. Similarly, in the study by Hetet et al,10 information on the
presence of diabetes was absent. Because of the complete-case
analysis, these studies were therefore automatically excluded from
the fully adjusted models. For better comparisons, we therefore also
presented minimally adjusted models (including study) without these
2 studies.
Sensitivity analyses were performed to assess sensitivity of the
ORs to the individual studies by excluding 1 study at a time.
As a secondary hypothesis, we investigated effect modification by
modeling the association between several classic cardiovascular risk
factors and CHD risk within strata of HFE genotypes (carriage of 0,
1, or 2 mutated alleles). The probability value for multiplicative
interaction was based on the likelihood ratio test comparing models
with and without interaction terms. Ideally, we would use strata of
HFE genotypes to distinguish effects within C282Y/wild-type and
C282Y/H63D subjects. However, despite the fact this is the largest
study to date, numbers of cases were still insufficient for reliable
statistical analyses. Therefore, we recategorized HFE genotypes into
noncarriers (wild-type/wild-type), carriers of 1 “risk” allele (H63D/
wild-type, C282Y/wild-type), and carriers of 2 risk alleles (H63D/
H63D, C282Y/H63D, C282Y/C282Y).
All analyses were conducted with the use of SAS statistical
software version 9.1 (SAS Institute, Cary, NC). Reported probability
values are 2-sided, and P0.05 was considered statistically signifi-
cant. The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the manuscript as
written.
Results
Our search strategy in PubMed resulted in 58 articles. When
the formulated criteria were applied to these articles, 13
eligible studies8,10–12,14–22 were identified. We did not come
across any articles in the reference lists that were not already
selected by our PubMed search. In addition, data from 1
unpublished study were included.23 All of the studies agreed
to participate and, with the exception of 3,14,16,17 were able to
provide the individual patient data, making the total number
of data sets included in the joint analyses 11.
The characteristics of the included studies and participants
are listed in Table 1. Control C282Y genotype frequencies of
most studies were in Hardy-Weinberg equilibrium, except for
the UK study of Hetet et al10 (P0.04) and Waalen et al18
(P0.03). Hardy-Weinberg equilibrium of the data of Gunn
et al22 was marginally significant (P0.08). Control H63D
genotype frequencies of all studies were in Hardy-Weinberg
equilibrium, although 3 were marginally significant (van der
A et al8 [P0.06], Candore et al11 [P0.08], and Waalen et
al18 [P0.06]). The reported frequencies of the 282Y allele
ranged from 0.0% in the south of Italy to 10.7% (95% CI,
8.8% to 12.6%) in North Glasgow, Scotland, showing a
distinct north-south gradient across Europe. The allelic fre-
quency of the H63D mutation varied much less, showing the
lowest frequency again in the south of Italy (12.5%; 95% CI,
9.3% to 15.7%) and in Denmark (12.5%; 95% CI, 12.0% to
13.0%) and the highest in France (17.5%; 95% CI, 13.3% to
22.2%).
Table 2 shows the population characteristics of the IPD






Type, n (%) H63D/Wild-Type, n (%) H63D/H63D, n (%)
C282Y/Wild-
Type, n (%) C282Y/H63D, n (%) C282Y/C282Y, n (%)
358 (100) 245 (68) 94 (26) 12 (3) 6 (2) 1 (1) 
1134 (100) 626 (55) 242 (21) 31 (3) 176 (16) 36 (3) 23 (2)
269 (100) 154 (57) 74 (28) 4 (1) 32 (12) 5 (2) 
266 (100) 166 (62) 64 (24) 5 (2) 23 (9) 6 (2) 2 (1)
2326 (100) 1358 (58) 567 (24) 48 (2) 293 (13) 44 (2) 16 (1)
31 049 (100) 19 356 (62) 7231 (23) 733 (2) 3039 (10) 551 (2) 139 (1)
379 (100) 271 (72) 91 (24) 7 (2) 9 (2) 1 (1) 
249 (100) 188 (76) 60 (24)  1 (1)  
1748 (100) 985 (56) 411 (24) 42 (2) 242 (14) 53 (3) 15 (1)
1586 (100) 935 (59) 359 (23) 29 (2) 223 (14) 36 (2) 4 (0)
11 619 (100) 7727 (67) 2400 (21) 202 (2) 1089 (9) 170 (1) 31 (1)
1672 (100) 1081 (65) 393 (24) 21 (1) 149 (9) 23 (1) 5 (1)
1225 (100) 770 (63) 268 (22) 31 (3) 131 (11) 21 (2) 4 (1)
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database, based on 43 366 controls and 10 514 CHD cases
(including n5724 AMI cases). Cases were more frequently
male, were on average slightly older, and showed a higher
prevalence of classic cardiovascular risk factors.
In Table 3, pooled ORs for the association between HFE
genotypes and cardiovascular disease are presented. Esti-
mates are shown for AMI and CHD risk and for combined
HFE genotypes, carriers of the 282Y allele, and carriers of the
63D allele (see Figures I to IV in the online-only Data
Supplement). Minimally adjusted models demonstrated a
small increased, although not statistically significant, risk of
AMI in compound heterozygous subjects compared with
wild-type subjects (OR1.10; 95% CI, 0.88 to 1.38). The OR
increased slightly when we further adjusted for age, sex, and
classic cardiovascular risk factors (OR1.15; 95% CI, 0.88
to 1.50). When 282Y and 63D alleles were examined sepa-
rately, carriers of the 282Y allele were not at increased risk
for AMI compared with noncarriers (OR0.95; 95% CI, 0.86
to 1.06), but for 63D carriers a small increased risk was seen
(OR1.08; 95% CI, 1.00 to 1.17) that approached statistical
significance (P0.07). Similar results were observed for
CHD. Inclusion of a cross-product term in the models showed
no evidence of interaction on a multiplicative scale between
the C282Y and H63D alleles. Sensitivity analyses, excluding
each study one at a time, were in general agreement with the
overall results.
The results of the analysis of risk modification by HFE
genotypes of the relation between classic risk factors and
cardiovascular events, overall and stratified by carriers of
varying numbers of risk alleles, are summarized in Table 4.
We observed no evidence for effect modification of the
relation between hypertension, smoking, diabetes, hypercho-
lesterolemia, gender, age, and AMI by HFE genotypes.
However, interaction between HFE genotypes (classified as
carriers of risk alleles) and hypertension for CHD risk
approached statistical significance (P0.05). The effect was
mainly ascribed to the study of Waalen et al18 (P0.005).
Hypertension was associated with an increased risk of CHD,
both in the presence and in the absence of HFE mutations.
The association, however, was attenuated in carriers of 2 HFE
risk alleles (OR1.22; 95% CI, 0.93 to 1.59) compared with
noncarriers (OR1.71; 95% CI, 1.59 to 1.83).
Discussion
Our present findings do not provide evidence for a material
role of HFE genotypes in cardiovascular disease risk. Despite
a large sample size, none of the HFE genotypes showed a
significant increase in risk compared with wild-types. Car-
riage of the H63D mutation was, however, related to a small
but statistically significant increased risk of CHD (OR1.08;
95% CI, 1.02 to 1.15) after adjustment for potential con-
founders. However, because we tested several hypotheses,
findings with probability values near the nominally signifi-
cant 0.05 level should be considered suggestive only.
We have examined the association between combined HFE
genotypes and CHD risk in a meta-analysis based on indi-
vidual patient data of 53 880 subjects from 11 different
studies. This enabled us to distinguish the effects of single
heterozygotes from compound heterozygotes. In our opinion,
this is an important distinction that needs to be made in view
of the evidence that significant differences in iron indices
exist between the 2 groups.24,25 Pooling of individual data of
the separate studies into a meta-analysis markedly increases
statistical power, not only for such analyses but also to
explore the possibility that the relation between cardiovascu-
lar risk factors and CHD risk depends on HFE genotypes.
Although this IPD meta-analysis is based on a large number
Table 2. Population Characteristics of the IPD Study
Characteristics Controls CHD Cases AMI Cases
No. of individuals 43 366 10 514 5724
Women, n (%) 22 830 (53) 3337 (32) 1356 (24)
Age, meanSD, y 56 14 63 11 62 11
Current smoking, n (%)* 8701 (20) 2951 (30) 2123 (38)
Hypertension, n (%)* 11 758 (27) 4496 (46) 2508 (46)
Hypercholesterolemia, n (%)* 23 850 (55) 6903 (70) 3993 (72)
Type 2 diabetes, n (%)* 1926 (5) 1102 (12) 635 (13)
Frequency 282Y allele† 6.3 (6.1–6.4) 6.6 (6.3–7.0) 6.9 (6.5–7.4)
Frequency 63D allele† 14.3 (14.1–14.5) 14.8 (14.3–15.3) 14.8 (14.1–15.4)
HFE genotype, n (%) 43 366 (100) 10 514 (100) 5724 (100)
Wild-type/wild-type 27 361 (63) 6501 (62) 3520 (62)
H63D/wild-type 9835 (23) 2419 (23) 1313 (23)
H63D/H63D 920 (2) 245 (2) 129 (2)
C282Y/wild-type 4313 (10) 1100 (10) 608 (11)
C282Y/H63D 744 (2) 203 (2) 121 (2)
C282Y/C282Y 193 (1) 46 (1) 33 (1)
*Percentages are based on the number of subjects with available data on this factor.
†Percentages and 95% CIs.
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of subjects, it may still have insufficient power to detect weak
genetic effects for certain HFE genotypes.
Previous studies showing an association between excess
iron and CHD risk have reported a stronger effect in the
presence of other cardiovascular risk factors such as smoking,
hypertension, or high levels of low-density lipoprotein.2,26–28
These synergistic associations may complicate the ability to
detect a possible association between iron and CHD. It might
well be possible that slightly elevated iron levels are only
deleterious in conjunction with increased oxidative stress
caused by additional cardiovascular risk factors. In this
meta-analysis, we observed no clear evidence for such effect
modification (showing a different effect of HFE genotypes on
CHD risk in individuals within different risk factor strata, or,
conversely, showing a different effect of classic risk factors
on CHD risk in persons with different HFE genotypes).
Unfortunately, even with a large sample size like ours, our
study was still limited by insufficient power to adequately
evaluate such interactions with individual HFE genotypes.
We were therefore compelled to lump together certain HFE
genotypes, which in a way ignores our original hypothesis
that the effect for compound heterozygous individuals might
be higher than for single heterozygous individuals. We cannot
exclude the possibility of an interaction between carriage of
HFE mutations and hypertension (P0.05). In our data,
hypertension seems to be a less important risk factor for CHD
when more risk alleles are present. This finding is in contrast
with the hypothesis that the effects of classic risk factors and
excess iron are synergistic.
To avoid bias, we attempted to include all available studies
in our meta-analysis. Unfortunately, 3 studies had to be
withdrawn from our study because the authors were unable to
retrieve their data.14,16,17 The published results of these
studies, however, are largely consistent with the findings of
our meta-analysis, suggesting that their inclusion would not
have changed our conclusions.
From a methodological point of view, one can criticize the
fact that we ignored different study designs in our statistical
analysis. However, we generally obtained similar results







Exclusion†‡ Model II§ Model III#
AMI
Wild-type/wild-type 3520 (62)  1.0 1.0 1.0 1.0
H63D/wild-type 1313 (23) 1.10 1.04 (0.97–1.13) 1.07 (0.99–1.16) 1.03 (0.96–1.12) 1.06 (0.97–1.16)
H63D/H63D 129 (2) 1.30 1.14 (0.92–1.42) 1.13 (0.90–1.42) 1.16 (0.93–1.44) 1.12 (0.88–1.42)
C282Y/wild-type 608 (11) 1.14 1.02 (0.92–1.13) 0.99 (0.89–1.11) 1.00 (0.90–1.11) 0.94 (0.84–1.07)
C282Y/H63D 121 (2) 1.30 1.10 (0.88–1.38) 1.10 (0.87–1.41) 1.09 (0.86–1.38) 1.15 (0.88–1.50)
C282Y/C282Y 33 (1) 1.63 1.01 (0.65–1.57) 0.97 (0.58–1.64) 1.12 (0.71–1.77) 0.94 (0.50–1.76)
282Y allele () 4962 (87)  1.0 1.0 1.0 1.0
282Y allele () 762 (13) 1.13 1.02 (0.93–1.12) 0.99 (0.89–1.09) 1.00 (0.91–1.11) 0.95 (0.86–1.06)
63D allele () 4161 (73)  1.0 1.0 1.0 1.0
63D allele () 1563 (27) 1.09 1.05 (0.98–1.13) 1.08 (1.00–1.16) 1.05 (0.97–1.12) 1.08 (1.00–1.17)
Total 5724 (100)     
CHD
Wild-type/wild-type 6501 (62)  1.0 1.0 1.0 1.0
H63D/wild-type 2419 (23) 1.07 1.06 (1.00–1.12) 1.07 (1.01–1.14) 1.06 (1.00–1.12) 1.07 (1.00–1.14)
H63D/H63D 245 (2) 1.23 1.19 (1.02–1.40) 1.19 (1.01–1.40) 1.19 (1.01–1.40) 1.16 (0.97–1.38)
C282Y/wild-type 1100 (10) 1.10 1.03 (0.95–1.11) 1.02 (0.94–1.10) 1.02 (0.94–1.10) 0.98 (0.90–1.07)
C282Y/H63D 203 (2) 1.23 1.08 (0.91–1.29) 1.08 (0.90–1.30) 1.09 (0.91–1.30) 1.12 (0.92–1.37)
C282Y/C282Y 46 (1) 1.48 0.84 (0.59–1.21) 0.79 (0.52–1.19) 0.92 (0.63–1.33) 0.78 (0.49–1.26)
282Y allele () 9165 (87)  1.0 1.0 1.0 1.0
282Y allele () 1349 (13) 1.10 1.01 (0.94–1.09) 0.99 (0.92–1.07) 1.01 (0.94–1.08) 0.97 (0.90–1.05)
63D allele () 7647 (73)  1.0 1.0 1.0 1.0
63D allele () 2867 (27) 1.07 1.07 (1.01–1.12) 1.08 (1.03–1.14) 1.07 (1.01–1.13) 1.08 (1.02–1.15)
Total 10 514 (100)     
*The OR that can be detected at 80% power at 2-sided P0.05.
†Adjusted for study (AMI analyses based on n49 090 subjects; CHD analyses based on n53 880 subjects).
‡Excluding the studies by Candore et al11 and Hetet et al10 (AMI analyses based on n47 059 subjects; CHD analyses based on n51 849 subjects).
§Adjusted for study, age, and gender (AMI analyses based on n49 068 subjects; CHD analyses based on n53 858 subjects).
Adjusted for study, age, gender, current smoking, hypertension, hypercholesterolemia, type 2 diabetes (AMI analyses based on n46 597; CHD analyses based
on n50 795 subjects).
#Assuming additive allele effects on a logistic scale (coding each genotype as an ordinal variable (0, 1, 2)) the results using model III for CHD were OR0.98
(0.91–1.06) for C282Y and OR1.08 (1.02–1.13) for H63D. For AMI the results were OR0.97 (0.87–1.07) for C282Y and OR1.07 (0.99–1.15) for H63D.
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when we selected only the case-control and cross-sectional
studies as when we included all designs (data not shown). The
reduction in number of subjects only slightly affected the
estimates for genotypes with the smallest prevalence. Sensi-
tivity analyses, excluding 1 study at a time, were in general
agreement with the overall results.
The frequency of the studied polymorphisms varies sub-
stantially across Europe, whereas the frequency of the out-
comes also varies across the European population, but in a
direction opposite to the allele frequency changes. This could
result in a population substructure masking an association.
We stratified for study in our analyses to address this issue.
However, substructure within studies could also mask asso-
ciations. This would be of greatest concern for populations
likely to be of mixed ancestry such as the studies from the
United States18 and Australia,19 consisting of subjects likely
to have ancestry from across Europe. We cannot exclude the
possibility that cryptic population structure is masking an
association.
Although not all published studies could be included, our
findings are comparable with 2 previous meta-analyses based
on aggregated data,8,29 and similar conclusions are drawn. For
63D carriers, the slightly higher risk (OR1.08; 95% CI,
1.02 to 1.15) that was observed in the current meta-analysis
could be in accordance with the effect estimated from the
aggregated data (OR1.03; 95% CI, 0.96 to 1.11) because
the CIs around the estimates still overlap.
Last year, results were published of the first large prospec-
tive randomized trial testing the hypothesis that a reduction in
body iron stores through phlebotomy has an effect on
all-cause mortality and death plus nonfatal myocardial infarc-
tion and stroke in patients with peripheral arterial disease.30
No statistically significant difference was observed between
the iron-reduction group and the control group for any end
point, although ferritin levels decreased significantly by 35%.
However, this study had only 68% power to detect a rather
large reduction in mortality (30%).
Previous studies found small differences in ferritin levels
between compound heterozygous and wild-type individuals,
which ranged between 19 and 80 g/L.25,31,32 However,
subjects with heterozygosity for C282Y and H63D typically
have normal iron stores.31–33 In a large trial, only 20% of male
heterozygotes and 8% of female heterozygotes had serum
ferritin levels that exceeded the 95th percentile values.34 It is
possible that, in addition to environmental effects on iron
metabolism, other genetic factors affect the severity of iron
overload. On the basis of our results, we are unable to reject
or support the original iron hypothesis for atherosclerosis
proposed by Sullivan, but further studies should be
illuminating.
In plasma of C282Y heterozygotes, a significantly in-
creased concentration of non–transferrin-bound iron has been
found.35 In vitro studies have demonstrated that this pro-
oxidative iron species is able to stimulate expression of
adhesion proteins on endothelial cells, which can be inhibited
with iron chelators.36,37 However, an association between
non–transferrin-bound iron levels and CHD could not be
demonstrated previously,38 nor did we find associations
between C282Y heterozygosity and AMI or CHD risk in this
study. Although experimental studies identified iron as one of
the numerous modifiers of vascular function, the exact
pathophysiological impact on early stages of atherosclerosis
and on cardiovascular outcomes remains uncertain. More-
over, the exact role of the HFE gene in cardiovascular
disease, either causal, for example, via new biomarkers such
as non–transferrin-bound iron or other forms of labile iron, or
indirect, via linkage or modification of nearby genes, needs to
be elucidated further.
In conclusion, the results of our large IPD meta-analysis do
not support the view that HFE gene mutations are associated
Table 4. Pooled ORs (95% CI) of the Association Between Conventional Cardiovascular Risk Factors and Cardiovascular Disease,
Overall and Stratified by HFE Genotypes
Factor Overall* Noncarriers† Carriers of 1 Risk Allele† Carriers of 2 Risk Alleles† P for Interaction
AMI
Hypertension 1.55 (1.43–1.67) 1.54 (1.40–1.70) 1.59 (1.39–1.81) 1.24 (0.85–1.80) 0.53
Smoking 1.37 (1.26–1.49) 1.34 (1.20–1.49) 1.39 (1.20–1.61) 1.65 (1.10–2.47) 0.64
Diabetes 2.42 (2.15–2.73) 2.50 (2.15–2.92) 2.32 (1.89–2.85) 2.10 (1.21–3.63) 0.77
Hypercholes. 4.66 (4.21–5.16) 4.72 (4.16–5.36) 4.53 (3.79–5.42) 4.59 (2.80–7.52) 0.71
Male gender 3.77 (3.47–4.10) 3.72 (3.35–4.14) 3.88 (3.34–4.51) 3.90 (2.62–5.79) 0.83
Age 58 y‡ 2.09 (1.93–2.25) 2.17 (1.96–2.39) 2.00 (1.75–2.29) 1.69 (1.18–2.44) 0.39
CHD
Hypertension 1.66 (1.57–1.75) 1.71 (1.59–1.83) 1.63 (1.48–1.79) 1.22 (0.93–1.59) 0.05
Smoking 1.16 (1.09–1.24) 1.17 (1.07–1.27) 1.12 (1.00–1.26) 1.38 (1.01–1.88) 0.52
Diabetes 2.07 (1.89–2.26) 2.08 (1.85–2.34) 2.13 (1.83–2.49) 1.53 (0.99–2.36) 0.30
Hypercholes. 3.14 (2.93–3.38) 3.29 (3.00–3.60) 2.92 (2.58–3.31) 2.96 (2.11–4.16) 0.31
Male gender 2.33 (2.20–2.46) 2.35 (2.19–2.53) 2.28 (2.06–2.51) 2.40 (1.85–3.13) 0.99
Age 58 y‡ 2.07 (1.96–2.19) 2.14 (1.99–2.30) 1.94 (1.76–2.14) 2.13 (1.63–2.78) 0.21
*Model includes carriage of HFE mutations, study, age (continuous), gender, current smoking, hypertension, hypercholesterolemia, and type 2 diabetes, except for
‡, in which the model includes age (dichotomous).
†Model includes study, age (continuous), gender, current smoking, hypertension, hypercholesterolemia, and type 2 diabetes, except for ‡, in which the model
includes age (dichotomous).
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with an increased risk of CHD or AMI. However, the power
of our study does not exclude weak genetic effects on CHD
(OR 1.23) or AMI (OR 1.30) by the C282Y/H63D
genotype.
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CLINICAL PERSPECTIVE
In the early eighties Sullivan proposed that an increase in body iron levels and subsequent oxidative stress may play a role
in the occurrence of cardiovascular disease. Up until 1996 blood markers of iron status and dietary iron intake were mostly
studied as indicators of iron exposure, but from that year on new opportunities were opened due to the discovery of the
hemochromatosis related gene HFE. The two most important mutations in the HFE gene, 282C3Y and 63H3D, have
both been associated with varying degrees of iron overload. However, their role as a risk factor for cardiovascular disease
remains subject to debate. In this Individual Patient Data (IPD) meta-analysis based on more than 10,000 documented cases
of CHD (of which almost 6,000 AMI cases) from eleven observational studies, we found no evidence for a material role
of HFE genotypes in cardiovascular disease risk. However, the power of our study does not exclude weak genetic effects
on CHD (odds ratio 1.23) or AMI (odds ratio 1.30) by the C282Y/H63D genotype.
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Figure I. Forrest plot of the association of C282Y carriage with CHD risk. 
 
 
Figure II. Forrest plot of the association of H63D carriage with CHD risk. 
 
H63D carriers Non carriers
Study Year CHD cases/N  CHD cases/N OR with 95% CI
Battiloro et al 2000 51/107 120/251 0,99 (0,63  to  1,56)
Hetet et al (UK) 2001 154/309 410/825 1,01 (0,77  to  1,31)
Heter et al (Fr) 2001 44/83 108/186 0,81 (0,48  to  1,37)
Fox et al 2002 81/659 192/1667 1,08 (0,82  to  1,42)
Claeys et al 2002 47/75 130/191 0,79 (0,45  to  1,38)
Waalen et al 2002 965/8515 2321/22534 1,11 (1,03  to  1,21)
Candore et al (North) 2003 37/99 135/280 0,64 (0,4  to  1,03)
Candore et al (South) 2003 17/60 60/189 0,85 (0,45  to  1,61)
Campbell et al 2003 366/506 889/1242 1,04 (0,82  to  1,31)
Gunn et al 2004 131/424 351/1162 1,03 (0,81  to  1,31)
Ellervik et al 2005 885/2772 2654/8847 1,09 (1  to  1,2)
Van der A et al 2006 46/437 161/1235 0,78 (0,55  to  1,11)
Cobbaert et al np 43/320 116/905 1,06 (0,73  to  1,54)
Pooled 2867/14366 7647/39514 1,07 (1,01 to 1,12)
0,1 1 10
OR (log scale)
Forest plot - OR (MH)
C282Y carriers Non carriers
Study Year CHD cases/N CHD cases/N OR with 95% CI
Battiloro et al 2000 4/7 167/351 1,47 (0,32  to  6,66)
Hetet et al (UK) 2001 130/235 434/899 1,33 (0,99  to  1,77)
Heter et al (Fr) 2001 22/37 130/232 1,15 (0,57  to  2,33)
Fox et al 2002 40/353 233/1973 0,95 (0,67  to  1,36)
Claeys et al 2002 22/31 155/235 1,26 (0,56  to  2,87)
Waalen et al 2002 378/3729 2908/27320 0,95 (0,85  to  1,06)
Candore et al (North) 2003 3/10 169/369 0,51 (0,13  to  1,99)
Candore et al (South) 2003 1/1 76/248 6,76 (0,27  to  167,94)
Campbell et al 2003 210/310 1045/1438 0,79 (0,61  to  1,03)
Gunn et al 2004 81/263 401/1323 1,02 (0,77  to  1,36)
Ellervik et al 2005 414/1290 3125/10329 1,09 (0,96  to  1,23)
Van der A et al 2006 25/177 182/1495 1,19 (0,76  to  1,86)
Cobbaert et al np 19/156 140/1069 0,92 (0,55  to  1,54)
Pooled 1349/6599 9165/47281 1,01 (0,94 to 1,08)
0,1 1 10 100 1000
OR (log scale)
Forest plot - OR (MH)
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C282Y carriers Non carriers
Study Year AMI cases/N AMI cases/N OR with 95% CI
Battiloro et al 2000 4/7 167/351 1,47 (0,32  to  6,66)
Hetet et al (UK) 2001 130/235 434/899 1,33 (0,99  to  1,77)
Heter et al (Fr) 2001 22/37 130/232 1,15 (0,57  to  2,33)
Fox et al 2002 18/331 155/1895 0,65 (0,39  to  1,07)
Claeys et al 2002 22/31 155/235 1,26 (0,56  to  2,87)
Waalen et al 2002 127/3478 994/25406 0,93 (0,77  to  1,12)
Candore et al (North) 2003 3/10 169/369 0,51 (0,13  to  1,99)
Candore et al (South) 2003 1/1 76/248 6,76 (0,27  to  167,94)
Campbell et al 2003 139/239 689/1082 0,79 (0,6  to  1,05)
Gunn et al 2004 70/252 341/1263 1,04 (0,77  to  1,41)
Ellervik et al 2005 200/1076 1482/8686 1,11 (0,94  to  1,31)
Van der A et al 2006 10/162 59/1372 1,46 (0,73  to  2,92)
Cobbaert et al np 16/153 111/1040 0,98 (0,56  to  1,7)
Pooled 762/6012 4962/43078 1,02 (0,93 to 1,12)
0,1 1 10 100 1000
OR (log scale)
Forest plot - OR (MH)
H63D carriers Non carriers
Study Year AMI cases/N AMI cases/N OR with 95% CI
Battiloro et al 2000 51/107 120/251 0,99 (0,63  to  1,56)
Hetet et al (UK) 2001 154/309 410/825 1,01 (0,77  to  1,31)
Heter et al (Fr) 2001 44/83 108/186 0,81 (0,48  to  1,37)
Fox et al 2002 49/627 124/1599 1,01 (0,71  to  1,42)
Claeys et al 2002 47/75 130/191 0,79 (0,45  to  1,38)
Waalen et al 2002 338/7888 783/20996 1,16 (1,01  to  1,32)
Candore et al (North) 2003 37/99 135/280 0,64 (0,4  to  1,03)
Candore et al (South) 2003 17/60 60/189 0,85 (0,45  to  1,61)
Campbell et al 2003 252/392 576/929 1,1 (0,86  to  1,41)
Gunn et al 2004 108/401 303/1114 0,99 (0,76  to  1,28)
Ellervik et al 2005 422/2309 1260/7453 1,1 (0,97  to  1,24)
Van der A et al 2006 16/407 53/1127 0,83 (0,47  to  1,47)
Cobbaert et al np 28/305 99/888 0,81 (0,52  to  1,25)
Pooled 1563/13062 4161/36028 1,05 (0,98 to 1,13)
0,1 1 10
OR (log scale)
Forest plot - OR (MH)
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